Which has stronger earnings and valuation, BVS or PDEX?

Bioventus has higher revenue and earnings than Pro-Dex. Pro-Dex is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 1.28 $22.73M $0.41 21.24 Pro-Dex $66.59M 3.08 $8.98M $3.62 17.78

Is BVS or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 29.97% beat Pro-Dex's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 4.94% 29.97% 9.52% Pro-Dex 16.08% 22.78% 14.30%

Does the media prefer BVS or PDEX?

In the previous week, Pro-Dex had 1 more articles in the media than Bioventus. MarketBeat recorded 2 mentions for Pro-Dex and 1 mentions for Bioventus. Bioventus' average media sentiment score of 0.00 equaled Pro-Dex'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pro-Dex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, PDEX or CBLL?

Pro-Dex has higher earnings, but lower revenue than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $66.59M 3.08 $8.98M $3.62 17.78 CeriBell $89.06M 7.68 -$53.41M -$1.63 N/A

Is PDEX or CBLL more profitable?

Pro-Dex has a net margin of 16.08% compared to CeriBell's net margin of -63.51%. Pro-Dex's return on equity of 22.78% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 16.08% 22.78% 14.30% CeriBell -63.51% -38.19% -30.92%

Does the media favor PDEX or CBLL?

In the previous week, CeriBell had 1 more articles in the media than Pro-Dex. MarketBeat recorded 3 mentions for CeriBell and 2 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 0.00 beat CeriBell's score of -0.04 indicating that Pro-Dex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CeriBell 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PDEX or SSII?

In the previous week, Pro-Dex and Pro-Dex both had 2 articles in the media. SS Innovations International's average media sentiment score of 0.63 beat Pro-Dex's score of 0.00 indicating that SS Innovations International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SS Innovations International 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, PDEX or SIBN?

Pro-Dex has higher earnings, but lower revenue than SiBone. SiBone is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $66.59M 3.08 $8.98M $3.62 17.78 SiBone $200.93M 3.50 -$18.90M -$0.39 N/A

Is PDEX or SIBN more profitable?

Pro-Dex has a net margin of 16.08% compared to SiBone's net margin of -8.10%. Pro-Dex's return on equity of 22.78% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 16.08% 22.78% 14.30% SiBone -8.10% -9.56% -7.06%

Does the media favor PDEX or SIBN?

In the previous week, Pro-Dex had 1 more articles in the media than SiBone. MarketBeat recorded 2 mentions for Pro-Dex and 1 mentions for SiBone. Pro-Dex's average media sentiment score of 0.00 equaled SiBone'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SiBone 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, BBNX or PDEX?

Pro-Dex has lower revenue, but higher earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beta Bionics $100.25M 6.17 -$73.20M -$1.51 N/A Pro-Dex $66.59M 3.08 $8.98M $3.62 17.78

Is BBNX or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to Beta Bionics' net margin of -60.27%. Pro-Dex's return on equity of 22.78% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -60.27% -23.00% -20.55% Pro-Dex 16.08% 22.78% 14.30%

Does the media prefer BBNX or PDEX?

In the previous week, Beta Bionics had 6 more articles in the media than Pro-Dex. MarketBeat recorded 8 mentions for Beta Bionics and 2 mentions for Pro-Dex. Beta Bionics' average media sentiment score of 0.80 beat Pro-Dex's score of 0.00 indicating that Beta Bionics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pro-Dex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pro-Dex (PDEX) Competitors

$64.37 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$64.30 -0.07 (-0.11%)

As of 06/18/2026 06:53 PM Eastern

Compare

PDEX vs. BVS, CBLL, SSII, SIBN, and BBNX

Should you buy Pro-Dex stock or one of its competitors? MarketBeat compares Pro-Dex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pro-Dex include Bioventus (BVS), CeriBell (CBLL), SS Innovations International (SSII), SiBone (SIBN), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry.

How does Pro-Dex compare to Bioventus?

Bioventus (NASDAQ:BVS) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

In the previous week, Pro-Dex had 1 more articles in the media than Bioventus. MarketBeat recorded 2 mentions for Pro-Dex and 1 mentions for Bioventus. Bioventus' average media sentiment score of 0.00 equaled Pro-Dex'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pro-Dex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pro-Dex has a net margin of 16.08% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 29.97% beat Pro-Dex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
Pro-Dex	16.08%	22.78%	14.30%

Bioventus has higher revenue and earnings than Pro-Dex. Pro-Dex is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.28	$22.73M	$0.41	21.24
Pro-Dex	$66.59M	3.08	$8.98M	$3.62	17.78

Bioventus has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market.

Bioventus currently has a consensus target price of $14.20, indicating a potential upside of 63.03%. Pro-Dex has a consensus target price of $70.00, indicating a potential upside of 8.75%. Given Bioventus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Bioventus is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

62.9% of Bioventus shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 33.0% of Bioventus shares are held by company insiders. Comparatively, 45.9% of Pro-Dex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Bioventus beats Pro-Dex on 10 of the 16 factors compared between the two stocks.

How does Pro-Dex compare to CeriBell?

Pro-Dex (NASDAQ:PDEX) and CeriBell (NASDAQ:CBLL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

In the previous week, CeriBell had 1 more articles in the media than Pro-Dex. MarketBeat recorded 3 mentions for CeriBell and 2 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 0.00 beat CeriBell's score of -0.04 indicating that Pro-Dex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CeriBell	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pro-Dex has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market. Comparatively, CeriBell has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Pro-Dex has a net margin of 16.08% compared to CeriBell's net margin of -63.51%. Pro-Dex's return on equity of 22.78% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
CeriBell	-63.51%	-38.19%	-30.92%

Pro-Dex currently has a consensus target price of $70.00, indicating a potential upside of 8.75%. CeriBell has a consensus target price of $22.20, indicating a potential upside of 23.13%. Given CeriBell's stronger consensus rating and higher possible upside, analysts clearly believe CeriBell is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Pro-Dex has higher earnings, but lower revenue than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$66.59M	3.08	$8.98M	$3.62	17.78
CeriBell	$89.06M	7.68	-$53.41M	-$1.63	N/A

15.3% of Pro-Dex shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by company insiders. Comparatively, 20.1% of CeriBell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Pro-Dex beats CeriBell on 9 of the 17 factors compared between the two stocks.

How does Pro-Dex compare to SS Innovations International?

Pro-Dex (NASDAQ:PDEX) and SS Innovations International (NASDAQ:SSII) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Pro-Dex has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$66.59M	3.08	$8.98M	$3.62	17.78
SS Innovations International	$42.49M	16.34	-$12.13M	-$0.05	N/A

Pro-Dex has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market. Comparatively, SS Innovations International has a beta of -1.88, indicating that its stock price is 288% less volatile than the broader market.

In the previous week, Pro-Dex and Pro-Dex both had 2 articles in the media. SS Innovations International's average media sentiment score of 0.63 beat Pro-Dex's score of 0.00 indicating that SS Innovations International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SS Innovations International	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

15.3% of Pro-Dex shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pro-Dex has a net margin of 16.08% compared to SS Innovations International's net margin of -20.69%. Pro-Dex's return on equity of 22.78% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
SS Innovations International	-20.69%	-23.00%	-13.18%

Pro-Dex presently has a consensus price target of $70.00, indicating a potential upside of 8.75%. SS Innovations International has a consensus price target of $7.00, indicating a potential upside of 101.73%. Given SS Innovations International's higher probable upside, analysts plainly believe SS Innovations International is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Pro-Dex beats SS Innovations International on 12 of the 15 factors compared between the two stocks.

How does Pro-Dex compare to SiBone?

Pro-Dex (NASDAQ:PDEX) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Pro-Dex has higher earnings, but lower revenue than SiBone. SiBone is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$66.59M	3.08	$8.98M	$3.62	17.78
SiBone	$200.93M	3.50	-$18.90M	-$0.39	N/A

Pro-Dex has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, SiBone has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

Pro-Dex presently has a consensus price target of $70.00, indicating a potential upside of 8.75%. SiBone has a consensus price target of $23.00, indicating a potential upside of 45.20%. Given SiBone's stronger consensus rating and higher possible upside, analysts clearly believe SiBone is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Pro-Dex had 1 more articles in the media than SiBone. MarketBeat recorded 2 mentions for Pro-Dex and 1 mentions for SiBone. Pro-Dex's average media sentiment score of 0.00 equaled SiBone'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SiBone	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pro-Dex has a net margin of 16.08% compared to SiBone's net margin of -8.10%. Pro-Dex's return on equity of 22.78% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
SiBone	-8.10%	-9.56%	-7.06%

15.3% of Pro-Dex shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 45.9% of Pro-Dex shares are held by insiders. Comparatively, 4.0% of SiBone shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Pro-Dex beats SiBone on 8 of the 15 factors compared between the two stocks.

How does Pro-Dex compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Beta Bionics has a beta of 3.4, meaning that its stock price is 240% more volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market.

Beta Bionics presently has a consensus target price of $19.70, suggesting a potential upside of 41.93%. Pro-Dex has a consensus target price of $70.00, suggesting a potential upside of 8.75%. Given Beta Bionics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Beta Bionics is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pro-Dex has lower revenue, but higher earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	6.17	-$73.20M	-$1.51	N/A
Pro-Dex	$66.59M	3.08	$8.98M	$3.62	17.78

In the previous week, Beta Bionics had 6 more articles in the media than Pro-Dex. MarketBeat recorded 8 mentions for Beta Bionics and 2 mentions for Pro-Dex. Beta Bionics' average media sentiment score of 0.80 beat Pro-Dex's score of 0.00 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pro-Dex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pro-Dex has a net margin of 16.08% compared to Beta Bionics' net margin of -60.27%. Pro-Dex's return on equity of 22.78% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Pro-Dex	16.08%	22.78%	14.30%

15.3% of Pro-Dex shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by company insiders. Comparatively, 45.9% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Beta Bionics beats Pro-Dex on 9 of the 17 factors compared between the two stocks.

Get Pro-Dex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PDEX vs. The Competition

Export

Metric	Pro-Dex	MED/DENTAL Industry	Medical Sector	NASDAQ Exchange
Market Cap	$205.52M	$16.71B	$6.43B	$12.60B
Dividend Yield	N/A	1.35%	2.68%	5.81%
P/E Ratio	17.78	18.09	24.75	24.44
Price / Sales	3.08	2.33	529.79	110.16
Price / Cash	20.53	13.76	45.07	55.09
Price / Book	5.73	3.28	10.80	6.58
Net Income	$8.98M	$534.24M	$3.57B	$337.17M
7 Day Performance	3.49%	-1.86%	0.72%	0.83%
1 Month Performance	2.81%	2.79%	0.41%	2.25%
1 Year Performance	58.78%	1.91%	29.34%	36.14%

Pro-Dex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PDEX Pro-Dex	1.9925 of 5 stars	$64.37 flat	$70.00 +8.7%	+58.8%	$205.52M	$66.59M	17.78	140	News Coverage
BVS Bioventus	4.2265 of 5 stars	$8.72 +1.4%	$14.20 +62.8%	N/A	$718.40M	$568.09M	11.47	1,200	Positive News Analyst Forecast
CBLL CeriBell	2.3892 of 5 stars	$17.92 -3.6%	$22.20 +23.9%	+0.7%	$705.35M	$89.06M	N/A	N/A
SSII SS Innovations International	2.4448 of 5 stars	$3.47 -1.4%	$7.00 +101.7%	-49.9%	$704.46M	$42.49M	N/A	4	News Coverage Positive News Analyst Downgrade
SIBN SiBone	1.7711 of 5 stars	$15.41 +1.9%	$23.00 +49.3%	-3.4%	$670.56M	$200.93M	N/A	350

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PDEX) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pro-Dex (PDEX) Competitors